Founded in 2010, Amoéba is an innovative industrial greentech specialised in the treatment of microbiological risk of natural resources. Our biosolutions are based on a unique micro-organism, the amoeba Willaertia magna C2c Maky. Thanks to our scientific, industrial and commercial know-how, we are able to provide biological alternatives for different applications and industries. 𝙊𝙐𝙍 𝙎𝙊𝙇𝙐𝙏𝙄𝙊𝙉𝙎 💄 Cosmetics : Our latest innovation offers anti-aging and UV protection properties. In October 2023, in vitro studies showed that this lysate stimulates cellular functions, activates wound healing genes, promotes hyaluronic acid synthesis, and enhances anti-infective immunity. These benefits were confirmed in a spring 2024 clinical study, with statistically significant results. Amoéba has successfully registered this ingredient on the INCI list, facilitating its commercialization and establishing it as a key player in innovative skincare solutions. 🌱 Biocontrol "AXPERA": Our second technology enables plant protection in agriculture and is based on the antifungal properties of the amoeba in its lysed (non-living) form. In 2022, the US Environmental Protection Agency (US EPA) has granted approval for the use of our solution in agriculture in the USA. In the same year, Austria issued a positive recommendation for the approval of our active substance in Europe. With this innovation, Amoéba contributes to an efficient, secure and more virtuous biological agriculture. 💧 Biocide "BIOMEBA": This historical application, initiated at the foundation of the company, enables the treatment of water in cooling towers and uses the amoeba Willaertia magna C2c Maky in its living form. In 2022, the US EPA has approved the use of our active substance in closed cooling systems in the USA, making our solution the first biological biocide approved for global industrial water treatment. Youtube 👉 @AmoebaNature X 👉 @AmoebaNature
| Website | https://amoeba-nature.com |
| Revenue | $8.2 million |
| Employees | 37 (10 on RocketReach) |
| Founded | 2010 |
| Industry | Biotechnology Research |
| Competitors | Thermo Fisher Scientific, Veolia, Ecolab, Merck Group, Xylem, Danaher Corporation, SUEZ, PerkinElmer, Inc., Bio-Rad Laboratories, Geno +30 more (view full list) |
Looking for a particular Amoéba employee's phone or email?
The Amoéba annual revenue was $8.2 million in 2026.
Jean-François Doucet is the Directeur général of Amoéba.
10 people are employed at Amoéba.